Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437116 | 1.00 | NMT2 (0.44) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29590365 | 0.95 | SIRT6 (0.45) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29388582 | 0.86 | SIRT6 (0.44) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL30537468 | 0.85 | ERAP2 (0.45) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569500 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569342 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569082 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29871873 | 0.84 | SIRT6 (0.58) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL31099442 | 0.84 | SIRT6 (0.47) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29531200 | 0.84 | SIRT6 (0.47) | NMT2NMT1SIRT6SIRT1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| CN-120189524-A | Bispecific antibody-drug conjugate targeting B7H3 and EGFR and application thereof | 信达生物制药(苏州)有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119564878-A | Bioactive substance conjugate, preparation method and application thereof | 苏州宜联生物医药有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119504997-A | Bioactive substance conjugate, preparation method and application thereof | 苏州宜联生物医药有限公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | claimed |
| WO-2024153185-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING BCL-2 FAMILY PROTEOLYSIS AGENT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-07-25 | — | — | WO | claimed |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | claimed |
| US-20230357763-A1 | Morpholinos with Increased Delivery Efficiency | MORPHOLINO THERAPEUTICS LLC | 2023-11-09 | — | — | US | claimed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | claimed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | claimed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | claimed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | claimed |
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| CN-115279417-A | Bioactive substance conjugate and preparation method and application thereof | 苏州宜联生物医药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | TNFRSF9, F13B, FCGR1A | NMT2 760/4885NMT1 807/4885SIRT6 1555/4885 |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | NMT2 305/4885NMT1 451/4885SIRT6 2481/4885 |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | EPCAM, CNTN1, STX18 | NMT2 949/4885NMT1 1445/4885SIRT6 3754/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | NMT2 104/4885NMT1 94/4885SIRT6 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.